Abstract
The comparative in vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone, was evaluated against 511 clinical isolates. MICs of trovafloxacin were fourfold higher than those of ciprofloxacin for 184Enterobacteriaceae and 110 non-fermentative gram-negative bacilli. However, trovafloxacin was 16-fold more active than ciprofloxacin against 162 gram-positive staphylococci, pneumococci, streptococci, and enterococci, and two- to fourfold more active againstHaemophilus influenzae andMoraxella catarrhalis. MICs of trovafloxacin were correspondingly higher for strains with acquired resistance to ciprofloxacin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349–353.
Eliopoulos GM, Klimm K, Eliopoulos T, Ferraro MJ, Moellering RC: In vitro activity of CP 99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366–370.
Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP 99,219 compared to those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 1994, 38: 2471–2476.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Verbist, L., Verhaegen, J. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis. 15, 683–685 (1996). https://doi.org/10.1007/BF01691160
Issue Date:
DOI: https://doi.org/10.1007/BF01691160